SCHEMBL4156828

SCHEMBL4156828

CC(C)N(CC[C@H](c1ccccc1)c1cc(CCOc2ccc(CCNC[C@H](O[Si](C)(C)C(C)(C)C)c3ccc(O)c(CO)c3)cc2)ccc1O)C(C)C

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 18/20 0.71
CHRM3 P20309 9/20 0.71
ADRB1 P08588 5/20 0.42
ADRA1D P25100 1/20 0.39
LMNA P02545 1/20 0.39
ESR1 P03372 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
MAPT P10636 1/20 0.39
CHRM1 P11229 1/20 0.39
KCNE1 P15382 1/20 0.39
PTGS1 P23219 1/20 0.39
HRH2 P25021 1/20 0.39
HTR2A P28223 1/20 0.39
SLC6A4 P31645 1/20 0.39
ADRA1A P35348 1/20 0.39
HRH1 P35367 1/20 0.39
OPRK1 P41145 1/20 0.39
KCNQ1 P51787 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4149642 0.97 ADRB2 (0.77) ADRB2CHRM3ADRB1ADRA1DCHRM5
SCHEMBL4154452 0.90 CHRM3 (0.61) ADRB2CHRM3LMNAESR1CHRM2
SCHEMBL4149624 0.90 ADRB2 (0.67) ADRB2CHRM3ADRB1ADRA1DCHRM2
SCHEMBL4149628 0.90 ADRB2 (0.67) ADRB2CHRM3ADRB1ADRA1DCHRM2
SCHEMBL4157732 0.89 ADRB2 (0.61) ADRB2CHRM3ADRB1
SCHEMBL4141725 0.88 ADRB2 (0.55) ADRB2CHRM3ADRB1CHRM2CHRM1
SCHEMBL4149727 0.87 ADRB2 (0.91) ADRB2CHRM3ADRB1ADRA1D
SCHEMBL4149718 0.87 ADRB2 (0.91) ADRB2CHRM3ADRB1ADRA1D
SCHEMBL4156854 0.87 ADRB2 (0.67) ADRB2CHRM3LMNAESR1CHRM2
SCHEMBL4150206 0.86 ADRB2 (0.74) ADRB2CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612084-B2 Amine derivatives for the treatment of asthma and COPD PFIZER INC (US) 2009-11-03 US disclosed
US-7612084-B2 Amine derivatives for the treatment of asthma and COPD PFIZER INC (US) 2009-11-03 US disclosed
US-20090253739-A1 Amine Derivatives PFIZER INC 2009-10-08 US disclosed
US-20090253739-A1 Amine Derivatives PFIZER INC 2009-10-08 US disclosed
EP-1999107-A2 AMINE DERIVATIVES Pfizer Limited (GB) 2008-12-10 EP disclosed
US-20070265303-A1 Amine derivatives PFIZER LIMITED 2007-11-15 US disclosed
US-20070265303-A1 Amine derivatives PFIZER LIMITED 2007-11-15 US disclosed
WO-2007107828-A2 AMINE DERIVATIVES PFIZER LIMITED (GB) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265303-A1 Amine derivatives HNMT, HRH4, CMA1 ADRB2 93/4885CHRM3 169/4885ADRB1 71/4885
US-20090253739-A1 Amine Derivatives HNMT, HRH4, CMA1 ADRB2 93/4885CHRM3 169/4885ADRB1 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.